Dr. Gerber on the Rationale to Combine Immunotherapy With Radiation in Lung Cancer

Video

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

David Gerber, MD, professor of internal medicine, Hematology/Oncology Division, co-director, Experimental Therapeutics Program, UT Southwestern Medical Center, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

According to Gerber, there has always been clinical interest in combining these treatment modalities.

It appears that the efficacy of radiation therapy is dependent on aspects of the immune system, Gerber explains. Moreover, concurrent immunotherapy and radiation therapy can lead to synergistic effects. The radiation may result in the release of more antigens, which will make the cancer more recognizable by the immune system, concludes Gerber.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD